News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
MethylGene’s, HDAC Inhibitor, MGCD0103 Selected As A Leading Cancer Project By Windhover Survey
June 5, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MethylGene Inc. (TSX: MYG) today announced that Donald F. Corcoran, President and Chief Executive Officer of MethylGene, will present at Windhover's Therapeutics Alliance Oncology Conference in Atlanta at 12:10 p.m., ET on Wednesday, June 7, 2006.
Twitter
LinkedIn
Facebook
Email
Print
Events
MORE ON THIS TOPIC
Cancer
AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data
April 30, 2025
·
8 min read
·
BioSpace Editorial Staff
Duchenne muscular dystrophy
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings
March 27, 2025
·
8 min read
·
Heather McKenzie
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
March 19, 2025
·
6 min read
·
Heather McKenzie
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
·
4 min read
·
Heather McKenzie